Crystallization and preliminary X-ray diffraction studies of human cytochrome P450 reductase

被引:6
作者
Zhao, Q
Smith, G
Modi, S
Paine, M
Wolf, RC
Tew, D
Lian, LY
Primrose, WU
Roberts, GCK
Driessen, HPC
机构
[1] UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,IMPERIAL CANC RES FUND,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND
[2] UNIV DUNDEE,NINEWELLS HOSP & MED SCH,BIOMED RES CTR,ICRF,MOLEC PHARMACOL UNIT,DUNDEE DD1 9SY,SCOTLAND
[3] UNIV LEICESTER,DEPT BIOCHEM,CTR MECHANISMS HUMAN TOX,LEICESTER LE1 9HN,LEICS,ENGLAND
[4] UNIV LEICESTER,DEPT BIOCHEM,BIOL NMR CTR,LEICESTER LE1 9HN,LEICS,ENGLAND
[5] SMITH KLINE BEECHAM RES,WELWYN GARDEN CIT AR6 9AR,HERTS,ENGLAND
关键词
D O I
10.1006/jsbi.1996.0048
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The two functional domains of a cloned human fibroblast NADPH-cytochrome P450 reductase have been expressed in Escherichia coli and purified on the milligram scale for crystallization studies. One domain contains the cofactor FMN-binding site and the other contains the binding sites for cofactor FAD and substrate NADPH. Crystals of both domains have been obtained by the microbatch method. The crystals of the FMN domain belong to the monoclinic space group P2(1) with unit cell dimensions of a = 39.3 Angstrom, b = 51.5 Angstrom, c = 47.8 Angstrom, and beta = 105.7 degrees and have one molecule in the asymmetric unit. Diffraction data up to 2.3 Angstrom were collected with a merging residual on intensity of 9.3%. The crystals of the FAD/NADPH domain belong to the orthorhombic space group P2(1)2(1)2(1) with unit cell dimensions of a = 55.9 Angstrom, b = 58.6 Angstrom, c = 131.1 Angstrom and have one molecule in the asymmetric unit. Diffraction data up to 2.6 Angstrom were collected with a merging residual on intensity of 8.0%. (C) 1996 Academic Press, Inc.
引用
收藏
页码:320 / 325
页数:6
相关论文
共 38 条
[1]  
[Anonymous], ACTA CRYSTALLOGR D
[2]   METAL-AFFINITY SEPARATIONS - A NEW DIMENSION IN PROTEIN PROCESSING [J].
ARNOLD, FH .
BIO-TECHNOLOGY, 1991, 9 (02) :151-156
[3]   ENHANCEMENT OF DOXORUBICIN TOXICITY FOLLOWING ACTIVATION BY NADPH CYTOCHROME P450 REDUCTASE [J].
BARTOSZEK, A ;
WOLF, CR .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (07) :1449-1457
[4]   TIME-RESOLVED FLUORESCENCE SPECTROSCOPY OF NADPH CYTOCHROME-P-450 REDUCTASE - DEMONSTRATION OF ENERGY-TRANSFER BETWEEN THE 2 PROSTHETIC GROUPS [J].
BASTIAENS, PIH ;
BONANTS, PJM ;
MULLER, F ;
VISSER, AJWG .
BIOCHEMISTRY, 1989, 28 (21) :8416-8425
[5]  
BLIGH HFJ, 1990, CANCER RES, V50, P7789
[6]  
BLUMBERG WE, 1982, OXYGENASES OXYGEN ME, P333
[7]   A P-31-NUCLEAR-MAGNETIC-RESONANCE STUDY OF NADPH-CYTOCHROME-P-450 REDUCTASE AND OF THE AZOTOBACTER FLAVODOXIN FERREDOXIN-NADP+ REDUCTASE COMPLEX [J].
BONANTS, PJM ;
MULLER, F ;
VERVOORT, J ;
EDMONDSON, DE .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 190 (03) :531-537
[8]   CRYSTALLIZATION AND PRELIMINARY-X-RAY STUDIES OF NADPH-CYTOCHROME P450 REDUCTASE [J].
DJORDJEVIC, S ;
ROBERTS, DL ;
WANG, M ;
SHEA, T ;
CAMITTA, MGW ;
MASTERS, BSS ;
KIM, JJP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3214-3218
[9]  
ENOCH HG, 1979, J BIOL CHEM, V254, P8976
[10]  
ILAN Z, 1981, J BIOL CHEM, V256, P66